Posted by Michael Wonder on 30 Jan 2020
Corium announces FDA filing acceptance of new drug application for Adlarity (donepezil transdermal system) for the treatment of Alzheimer’s disease
27 January 2020 - Corium today announced that the U.S. FDA has accepted for filing the company’s new drug application for Adlarity (donepezil transdermal system), its lead investigational agent for the treatment of dementia of the Alzheimer’s type in patients with mild, moderate, and severe Alzheimer’s disease.
The FDA has set a Prescription Drug User Fee Act target action date of 30 July 2020.
